<DOC>
	<DOCNO>NCT00306631</DOCNO>
	<brief_summary>This phase 2 study determine antitumor activity , base objective rate , oral MKC-1 , administer twice daily 14 consecutive day every 4 week , patient advance metastatic breast carcinoma . The study also evaluate safety response duration patient , time tumor progression , overall survival patient follow MKC-1 therapy .</brief_summary>
	<brief_title>A Study Determine Antitumor Activity Evaluate Safety MKC-1</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm advanced metastatic adenocarcinoma breast 18 year old Karnofsky performance status great equal 70 % Radiographic physical examination evidence least one site unidimensionallymeasurable disease , use Response Evaluation Criteria Solid Tumors ( RECIST ) criterion Must fail taxane anthracycline , give sequentially combination , either adjuvant metastatic set All acute toxicity prior chemotherapy , surgery radiotherapy must resolve National Cancer Institute Common Toxicity Criteria ( NCI CTC ) Grade le equal 1 Lab result , within 10 day MKC1 administration : Hemoglobin le equal 9 g/dL Absolute neutrophil count great equal 1.5 x 10^9/L Platelet count great equal 75 x 10^9/L Serum creatinine less equal 1.5 x ULN ( upper limit normal ) AST le equal 2.5 x ULN Serum albumin great equal LLN ( low limit normal ) Total bilirubin less equal ULN Alkaline phosphatase less equal 2.5 x ULN Signed informed consent Preexisting hepatomegaly disease measure great equal 2 cm costal margin , secondary malignancy Administration cancer specific therapy within follow period prior study drug initiation : chemotherapy le 3 week prior hormonal therapy le one week prior radiation therapy le 2 week prior Be pregnant lactating ; employ effective birth control Known central nervous system ( CNS ) metastases unless treat , clinically stable require steroid Clinical evidence bowel obstruction , active uncontrolled malabsorption syndrome history total gastrectomy Administration investigational agent ( therapeutic diagnostic ) within 4 week prior receipt study medication Uncontrolled hypercalcemia ( serum calciumcorrected great 12 mg/dL ) Serious cardiac condition Any medical condition , investigator 's opinion would impose excessive risk patient Patients previous malignancy unless free recurrence least 5 year except basal cell carcinoma skin carcinomainsitu uterine cervix Treatment antiretroviral therapy metabolize CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Advanced Metastatic Breast Cancer</keyword>
</DOC>